Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy

Annals of Surgical Oncology

Volumn 16, Issue 10, 2009, Pages 2848-2855

  D'Amato, Thomas A ^a   Pettiford, Brian L ^b   Schuchert, Mathew J ^b   Parker, Ricardo ^c   Ricketts, William A ^c   Luketich, James D ^b   Landreneau, Rodney J ^b  

^a Forum Health   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Oncotech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DETERMINATION; EXTREME DRUG RESISTANCE ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME; TUMOR BIOPSY; VALIDATION PROCESS; CANCER STAGING; DRUG RESISTANCE; FOLLOW UP; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73349090276     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0608-0     Document Type: Article

References (25)

1. American Cancer Society. Cancer facts & figures 2008. Ameri-can Cancer Society, Atlanta, 2008.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-7.
3. Winton TL, Livingston R, Johnson D, et al. A prospective ran-domized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. N Engl J Med. 2005;352:2289-97.
4. Douillard J, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median fol-low-up. On behalf of the Adjuvant Navelbine International Trialist Association. ASCO annual meeting proceedings, Orlando, Florida, USA. J Clin Oncol. 2005;23:7013.
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, et al. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91.
6. Mehta R, Bomstein R, Yu I-R, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treatment. 2001;66:225-37.
7. Holloway R, Mehta R, Finkler N, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002;87:8-16.
8. Parker RJ, Fruehauf JP, Mehta R, et al. A prospective blinded study of predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neuro-Oncol. 2004;66:365-75
9. d'Amato TA, Landreneau RJ, McKenna RJ, et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small cell lung cancer. Ann Thor Surg. 2006;81:440-7
10. d'Amato TA, Landreneau RJ, Ricketts W, Huang W, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:352-63.
11. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th ed. Springer-Verlag, New York, 2002.
12. Schiller J, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8.
13. Kern D, Weisenthal L. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharacologic drug exposures. J Natl Cancer Inst. 1990;82:582-8.
14. Wilbur DW, Camacho ES, Hilliard DA, et al. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resis-tance assay measuring total tumour cell kill. Br J Cancer. 1992; 65:27-32.
15. Moon YW, Choi SH, Kim YT, Sohn JH, et al. Adenosine tri-phosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable non-small-cell lung cancer. Cancer. 2007;109:1829-35.
16. Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598 J Clin Oncol. 2004;22:1180-7.
17. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the lace col-laborative group. J Clin Oncol. 2008;26:3552-9.
18. Tsao MS, Aviel-Ronen S, Ding K, Lau D, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240-7.
19. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201-5.
20. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med. 2006;355:570-80.
21. Chen HY, Yu SL, Chen CH, Chang GC, et al. A five-gene sig-nature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11-20.
22. Boutros PC, Lau SK, Pintilie M, Liu N, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci. 2009;106:2824-8.
23. Schwartz AM, Henson DE. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines, 2nd ed. Chest. 2007;132(3 Suppl):78S-93S
24. d'Amato TA. Adjuvant chemotherapy and the role of chemore-sistance testing for stage I non-small cell lung cancer. Thorac Surg Clin. 2007;17:287-99.
25. Strauss G, Herndon J, Maddaus M, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24(18S): 7007.